why choose us

First received: September 07, 2023

Clinical Trial: Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Study Status: Completed

Recruit Status: RECRUITING

Condition: Anatomic Stage I Breast Cancer AJCC v8

Study Type: INTERVENTIONAL


Official Title: Dose Reduction of Docetaxel-Based Chemotherapy in Vulnerable Older Women With Early-Stage Breast Cancer (DOROTHY)

Brief Summary: This phase II trial tests how well dose-reduced docetaxel combined with cyclophosphamide works in treating older women with early stage (stage I-III) HER2 negative breast cancer vulnerable to toxicity.Chemotherapy drugs, such as docetaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.Docetaxel and cyclophosphamide are commonly used, but is not well tolerated at the standard dose and can…

Read more